BIOCYTOGEN PHARMACEUTICALS (BEIJING financial statements, including revenue, expenses, profit, and loss
The total revenue of 2315 for the last semiannual is 421.41 M HKD, and it's 14.01% higher compared to the previous semiannual. The net income of H2 23 is -208.66 M HKD.